{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:27:08Z","timestamp":1787678828932,"version":"build-2784847793"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ijid.2021.11.037","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T18:12:54Z","timestamp":1638295974000},"page":"142-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["High-dose gatifloxacin-based shorter treatment regimens for MDR\/RR-TB"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3191-9285","authenticated-orcid":false,"given":"Qi","family":"Nie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixuan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanshan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huidong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuping","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianguang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaolin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengfeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10150","key":"10.1016\/j.ijid.2021.11.037_bib0001","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"Ahmad","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ijid.2021.11.037_bib0002","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/230240bc-bcf3-46b2-9b21-2e6e584f7333","article-title":"Correction: Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients","volume":"9","author":"Ahuja","year":"2012","journal-title":"PLoS Med"},{"issue":"Suppl 13","key":"10.1016\/j.ijid.2021.11.037_bib0003","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1157\/13128781","article-title":"Tuberculosis multirresistente [Multidrug-resistant tuberculosis]","volume":"26","author":"Alcaide","year":"2008","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"7","key":"10.1016\/j.ijid.2021.11.037_bib0004","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00636-18","article-title":"Impact of clofazimine dosing on treatment shortening of the first-line regimen in a mouse model of tuberculosis","volume":"62","author":"Ammerman","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.ijid.2021.11.037_bib0005","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.5588\/ijtld.14.0100","article-title":"Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients","volume":"18","author":"Aung","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"issue":"9","key":"10.1016\/j.ijid.2021.11.037_bib0006","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.5588\/ijtld.15.0884","article-title":"Gatifloxacin for short, effective treatment of multidrug-resistant tuberculosis","volume":"20","author":"Chiang","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"issue":"11","key":"10.1016\/j.ijid.2021.11.037_bib0007","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1164\/rccm.201910-1960OC","article-title":"Early Bactericidal Activity of Different Isoniazid Doses for Drug Resistant TB (INHindsight): A Randomized Open-label Clinical Trial","volume":"201","author":"Dooley","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2021.11.037_bib0008","series-title":"Pure tone audiogram and interpretation [internet]","year":"2015"},{"key":"10.1016\/j.ijid.2021.11.037_bib0009","series-title":"ERLN-TB expert opinion on the use of the rapid molecular assays for the diagnosis of tuberculosis and detection of drug-resistance","year":"2013"},{"key":"10.1016\/j.ijid.2021.11.037_bib0010","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijantimicag.2006.11.011","article-title":"Arrhythmias associated with fluoroquinolone therapy","volume":"29","author":"Falagas","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2021.11.037_bib0011","doi-asserted-by":"crossref","unstructured":"Falzon D., Sch\u00fcnemann H.J., Harausz E., Gonz\u00e1lez-Angulo L., Lienhardt C., Jaramillo E., et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. The European Respiratory Journal. 2017 Mar 22;49(3):1602308. doi: 10.1183\/13993003.02308-2016. PMID: 28331043; PMCID: PMC5399349.","DOI":"10.1183\/13993003.02308-2016"},{"key":"10.1016\/j.ijid.2021.11.037_bib0012","series-title":"Determination that TEQLUIN (Gatifloxacin) was withdrawn from sale for reasons of safety or effectiveness","year":"2008"},{"issue":"1","key":"10.1016\/j.ijid.2021.11.037_bib0013","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1128\/JCM.44.1.201-205.2006","article-title":"Use of a mycobacteriophage-based assay for rapid assessment of susceptibilities of Mycobacterium tuberculosis isolates to isoniazid and influence of resistance level on assay performance","volume":"44","author":"Gal\u00ed","year":"2006","journal-title":"J Clin Microbiol"},{"issue":"9","key":"10.1016\/j.ijid.2021.11.037_bib0014","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1086\/424849","article-title":"Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling","volume":"190","author":"Gumbo","year":"2004","journal-title":"J Infect Dis"},{"issue":"Pt 11","key":"10.1016\/j.ijid.2021.11.037_bib0015","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1099\/jmm.0.46718-0","article-title":"Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA","volume":"55","author":"Guo","year":"2006","journal-title":"J Med Microbiol"},{"issue":"6","key":"10.1016\/j.ijid.2021.11.037_bib0016","doi-asserted-by":"crossref","first-page":"667","DOI":"10.5588\/ijtld.17.0830","article-title":"Increased risk of aminoglycoside-induced hearing loss in MDR-TB patients with HIV coinfection","volume":"22","author":"Hong","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"10.1016\/j.ijid.2021.11.037_bib0017","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1044\/2020_AJA-19-00103","article-title":"Prevalence of pre-existing hearing loss among patients with drug-resistant tuberculosis in South Africa","volume":"29","author":"Hong","year":"2020","journal-title":"Am J Audiol"},{"issue":"6","key":"10.1016\/j.ijid.2021.11.037_bib0018","first-page":"605","article-title":"Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis","volume":"10","author":"Johnson","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"10.1016\/j.ijid.2021.11.037_bib0019","first-page":"139","article-title":"A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis","volume":"12","author":"Katiyar","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"10.1016\/j.ijid.2021.11.037_bib0020","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S2213-2600(16)30423-4","article-title":"Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis","volume":"5","author":"Kendall","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.ijid.2021.11.037_bib0021","doi-asserted-by":"crossref","first-page":"517","DOI":"10.5588\/ijtld.14.0535","article-title":"High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon","volume":"19","author":"Kuaban","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"issue":"11","key":"10.1016\/j.ijid.2021.11.037_bib0022","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/cid\/cis664","article-title":"Fluoroquinolones and the risk of serious arrhythmia: a population-based study","volume":"55","author":"Lapi","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.ijid.2021.11.037_bib0023","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1128\/AAC.49.10.4068-4074.2005","article-title":"Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis isolates collected in Australia","volume":"49","author":"Lavender","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.11.037_bib0024","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ijid.2020.08.042","article-title":"Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen","volume":"100","author":"Lempens","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"10","key":"10.1016\/j.ijid.2021.11.037_bib0025","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.5588\/ijtld.14.0297","article-title":"False-positive rifampicin resistance on Xpert\u00ae MTB\/RIF caused by a silent mutation in the rpoB gene","volume":"18","author":"Mathys","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"10.1016\/j.ijid.2021.11.037_bib0026","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0041-3879(85)90040-6","article-title":"The action of antituberculosis drugs in short-course chemotherapy","volume":"66","author":"Mitchison","year":"1985","journal-title":"Tubercle"},{"issue":"13","key":"10.1016\/j.ijid.2021.11.037_bib0027","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","article-title":"A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis","volume":"380","author":"Nunn","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ijid.2021.11.037_bib0028","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.5588\/ijtld.13.0075","article-title":"High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses","volume":"18","author":"Piubello","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"issue":"11","key":"10.1016\/j.ijid.2021.11.037_bib0029","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.5588\/ijtld.17.0468","article-title":"The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?","volume":"21","author":"Reuter","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"10.1016\/j.ijid.2021.11.037_bib0030","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/jac\/dkv360","article-title":"Specific gyrA gene mutations predict poor treatment outcome in MDR-TB","volume":"71","author":"Rigouts","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.ijid.2021.11.037_bib0031","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1128\/AAC.39.11.2472","article-title":"Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis","volume":"39","author":"Rouse","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.11.037_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100268","article-title":"Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries","volume":"20","author":"Schw\u0153bel","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"3","key":"10.1016\/j.ijid.2021.11.037_bib0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119628","article-title":"Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review","volume":"10","author":"Seifert","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ijid.2021.11.037_bib0034","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/jac\/dkaa489","article-title":"Second-line injectable drugs for rifampicin-resistant tuberculosis: better the devil we know?","volume":"76","author":"Tahseen","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.ijid.2021.11.037_bib0035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5588\/ijtld.17.0498","article-title":"Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries","volume":"22","author":"Tr\u00e9bucq","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"10.1016\/j.ijid.2021.11.037_bib0036","doi-asserted-by":"crossref","first-page":"239","DOI":"10.5588\/ijtld.17.0660","article-title":"Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs","volume":"22","author":"Van Deun","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"10.1016\/j.ijid.2021.11.037_bib0037","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","article-title":"Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis","volume":"182","author":"Van Deun","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.ijid.2021.11.037_bib0038","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/cid\/ciz039","article-title":"Improved outcomes with high-dose isoniazid in multidrug-resistant tuberculosis treatment in Haiti","volume":"69","author":"Walsh","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.ijid.2021.11.037_bib0039","first-page":"453","article-title":"Study on the cross-resistance among 5 different fluroquinolones in ofloxacin-resistant Mycobacterium tuberculosis isolates[J]","volume":"36","author":"WANG","year":"2014","journal-title":"Chinese Journal of Antituberculosis"},{"key":"10.1016\/j.ijid.2021.11.037_bib0040","series-title":"Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis","year":"2014"},{"key":"10.1016\/j.ijid.2021.11.037_bib0041","series-title":"Definitions and reporting framework for tuberculosis \u20132013 revision: updated December 2014 and January 2020","year":"2013"},{"key":"10.1016\/j.ijid.2021.11.037_bib0042","series-title":"Global tuberculosis report","year":"2020"},{"key":"10.1016\/j.ijid.2021.11.037_bib0043","series-title":"WHO consolidated guidelines on tuberculosis module 4: treatment drug-resistant tuberculosis treatment","year":"2020"},{"key":"10.1016\/j.ijid.2021.11.037_bib0044","series-title":"WHO treatment guidelines for drug-resistant tuberculosis, 2016 update","year":"2016"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221008869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221008869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:04:49Z","timestamp":1761120289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971221008869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":44,"alternative-id":["S1201971221008869"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2021.11.037","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-dose gatifloxacin-based shorter treatment regimens for MDR\/RR-TB","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2021.11.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}